Number of babies born with opioid dependence has tripled in US, says CDC report
August 12, 2016Medical Communications, Research and Development CDC, addicted, babies, opioid dependence, opioids
A new report from the Centers for Disease Control and Prevention (CDC) has highlighted a sharp increase in the number …
Allergan set to acquire eye-care biotech ForSight VISION5
August 12, 2016Medical Communications, Sales and Marketing Allergan, ForSight VISION5, acquisition, biotech, eye care
Allergan has announced its acquisition of privately-held, clinical-stage eye-care biotech ForSight VISION5 for a $95 million upfront payment and a …
Novartis admits employees gave kickbacks to doctors in South Korea
August 12, 2016Medical Communications, Research and Development Novartis, kickbacks, south korea
Novartis has confirmed that six employees in South Korea gave kickbacks to doctors, as the current and former employees face …
Advaxis follows up Amgen deal with Phase IIa cancer trial success
August 12, 2016Medical Communications, Research and Development Advaxis, immunotherapy. cancer. Amgen
Advaxis, a US biotech in cancer immunotherapy development, has announced that its lead immunotherapy product axalimogene filolisbac (AXAL) has hit …
Gilead to work with Genmab on HIV targeting technology
August 12, 2016Medical Communications, Research and Development, Sales and Marketing Genmab, Gilead, HIV, duobody
Genmab has announced that it has entered into a collaboration deal with Gilead Sciences to use the DuoBody technology platform …
Thousands to benefit with new anti-clotting drug recommendation, says NICE
August 12, 2016Medical Communications, Sales and Marketing AstraZeneca, Brilique, ticagrelor
The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending AstraZeneca’s Brilique (ticagrelor) for people …
Valeant under criminal investigation
August 11, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, investigation
Valeant Pharmaceuticals International is currently under investigation by the US attorney’s office in Manhattan over suspicions that the firm intentionally …
FDA accepts Marathon’s Duchenne drug for priority review
August 11, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, deflazacort, marathon, marathon pharmaceuticals
Marathon Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted and granted a priority review for …
Heron Therapeutics gets FDA approval for chemotherapy-induced nausea drug
August 11, 2016Research and Development, Sales and Marketing FDA, chemotherapy-induced nausea, granisetron, heron therapeutics, sustol
Heron Therapeutics has announced that it has received US Food and Drug Administration (FDA) approval for Sustol (granisetron) for the …
Chronos Therapetics strengthens management with two new vice presidents
August 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Private biotech Chronos Therapeutics has announced two new additions to its management team; Dr Fraser Murray and Dr Timonthy Schulz-Utermoehl …
New senior VP, finance at Eli Lilly
August 10, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly
Eli Lilly has announced that Joshua Smiley is set to become senior vice president, finance, and treasurer from October 1, …
New Agilent expansion will ‘more than double’ nucleic acid API manufacture
August 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Agilent, expansion, manufacturing, oligonucleotide
Agilent Technologies is set to expand its pharmaceutical manufacturing operations with a 20-acre facility in Weld County, Colorado. The facility …
Interim analysis fails to show benefits for Lilly’s abemaciclib in advanced breast cancer
August 10, 2016Research and Development Eli Lilly, abemaciclib, breast cancer
Eli Lilly has announced that, after a pre-planned interim analysis for their Phase III MONARCH2 trial, investigators have decided to …
Valeant stock rises despite weak Q2 results
August 10, 2016Research and Development, Sales and Marketing Valeant, financial results
Valeant Pharmaceuticals’ share price in pre-market trading has risen 7.44% to $24.12 in the wake of its Q2 results announcement. …
Biogen names haemophilia spin-off Bioverativ
August 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, bioverativ
Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …
Experimental stem cell treatment shows promise in rheumatoid arthritis
August 10, 2016Research and Development Mesoblast, rheumatoid arthritis, stem cell treatment
Mesoblast has announced results from a Phase II clinical trial evaluating MPC-300-IV in patients with biologic refractory rheumatoid arthritis (RA) …
Old CDF drug not recommended in initial NICE guidance due to lack of evidence
August 10, 2016Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …
NICE recommends Amgen’s Imlygic for advanced skin cancer
August 9, 2016Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer
NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …
Helsinn and MEI Pharma join forces to develop leukaemia drug Pracinostat
August 9, 2016Manufacturing and Production, Research and Development Helsinn, MEI Pharma, Pracinostat, chronic myeloid leukaemia
Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …
New therapy wins EMA orphan drug designation for ALS
August 9, 2016Manufacturing and Production, Research and Development EMA, Ice Bucket Challenge, ab science, als, masitinib, oprhan drug designation
French pharma company AB Science has announced that the European Medicines Agency has granted orphan drug status to masitinib for …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
